Market Access News | pharmaphorum

News

AbbVie’s Tepkinly backed by NICE for DLBCL patients

AbbVie’s CD20xCD3 bispecific antibody Tepkinly has been recommended by NICE for NHS use as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an

News

FDA starts swift review of tumour-agnostic use of Enhertu

AstraZeneca and Daiichi Sankyo’s Enhertu could become the first therapy approved by the FDA for use in any HER2-positive cancer, regardless of its location in the body.

News

GSK’s Omjjara EU-cleared for splenomegaly in myelofibrosis

GSK’s $1.9 billion takeover of Sierra Oncology has delivered the first new product, with the EU approval of Omjjara for the treatment of enlarged spleen (splenomegaly) or

News

CHMP turns down Neuraxpharm, Apellis drugs

The EMA’s human medicines committee refused marketing approvals for two drugs from Neuraxpharm and Apellis at its January meeting, but both companies have said they will a

News

Britain will be first to get new Mounjaro device, says Lilly

Eli Lilly is just weeks away from launching Mounjaro in the UK, after getting approval from medicines regulator, the MHRA, for a new formulation of the drug as a treatment

News

Remote Parkinson’s monitoring tech backed by NICE

In its second guidance on digital health technologies within a week, NICE has endorsed five remote monitoring devices for patients with Parkinson’s disease that can be use

AbbVie’s Tepkinly backed by NICE for DLBCL patients

FDA starts swift review of tumour-agnostic use of Enhertu

GSK’s Omjjara EU-cleared for splenomegaly in myelofibrosis

CHMP turns down Neuraxpharm, Apellis drugs

Britain will be first to get new Mounjaro device, says Lilly

Remote Parkinson’s monitoring tech backed by NICE

FDA orders blindness risk warning to GLP-1 agonist labels

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks